83 related articles for article (PubMed ID: 14727239)
1. A prospective, single-arm, phase II clinical trial of intraoperative radiotherapy using a low-energy X-ray source for local advanced Laryngocarcinoma (ILAL): a study protocol.
Yang Y; Li L; Zheng Y; Liu Q; Wei X; Gong X; Wang W; Lin P
BMC Cancer; 2020 Aug; 20(1):734. PubMed ID: 32762662
[TBL] [Abstract][Full Text] [Related]
2. Mitigation of Radiation-Induced Epithelial Damage by the TLR5 Agonist Entolimod in a Mouse Model of Fractionated Head and Neck Irradiation.
Toshkov IA; Gleiberman AS; Mett VL; Hutson AD; Singh AK; Gudkov AV; Burdelya LG
Radiat Res; 2017 May; 187(5):570-580. PubMed ID: 28323577
[TBL] [Abstract][Full Text] [Related]
3. Amifostine Prophylaxis in Irradiated Breast Reconstruction: A Study of Oncologic Safety In Vitro.
Luby AO; Subramanian C; Buchman LK; Lynn JV; Urlaub KM; Nelson NS; Donneys A; Cohen MS; Buchman SR
Ann Plast Surg; 2020 Oct; 85(4):424-429. PubMed ID: 31850964
[TBL] [Abstract][Full Text] [Related]
4. External Beam Radiotherapy in High-risk Head-and-neck Cancers with Reduced Overall Treatment Time in Telecobalt Beam Quality.
Ravichandran R; Kannan RR
J Med Phys; 2023; 48(4):409-411. PubMed ID: 38223795
[No Abstract] [Full Text] [Related]
5. Current radiotherapy for recurrent head and neck cancer in the modern era: a state-of-the-art review.
Li Y; Jiang Y; Qiu B; Sun H; Wang J
J Transl Med; 2022 Dec; 20(1):566. PubMed ID: 36474246
[TBL] [Abstract][Full Text] [Related]
6. Interventions for preventing oral mucositis for patients with cancer receiving treatment.
Worthington HV; Clarkson JE; Bryan G; Furness S; Glenny AM; Littlewood A; McCabe MG; Meyer S; Khalid T
Cochrane Database Syst Rev; 2011 Apr; 2011(4):CD000978. PubMed ID: 21491378
[TBL] [Abstract][Full Text] [Related]
7. Intraoperative radiotherapy (IORT) with low-energy photons as a boost in patients with early-stage oral cancer with the indications for postoperative radiotherapy : treatment feasibility and preliminary results.
Rutkowski T; Wygoda A; Hutnik M; Składowski K; Wydmański J; Maciejewski A; Szymczyk C; Wierzgoń J; Orlef A; Maciejewski B
Strahlenther Onkol; 2010 Sep; 186(9):496-501. PubMed ID: 20803185
[TBL] [Abstract][Full Text] [Related]
8. Intraoperative radiation therapy (IORT) in head and neck cancer: A systematic review.
Kyrgias G; Hajiioannou J; Tolia M; Kouloulias V; Lachanas V; Skoulakis C; Skarlatos I; Rapidis A; Bizakis I
Medicine (Baltimore); 2016 Dec; 95(50):e5035. PubMed ID: 27977569
[TBL] [Abstract][Full Text] [Related]
9. Intraoperative radiation therapy in the multimodality approach to upper aerodigestive tract cancer.
Carter YM; Jablons DM; DuBois JB; Thomas CR
Surg Oncol Clin N Am; 2003 Oct; 12(4):1043-63. PubMed ID: 14989132
[TBL] [Abstract][Full Text] [Related]
10. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer.
Hu K; Ship JA; Harrison LB
Semin Oncol; 2003 Dec; 30(6 Suppl 18):40-8. PubMed ID: 14727239
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data.
Thorstad WL; Haughey B; Chao KS
Semin Oncol; 2003 Dec; 30(6 Suppl 18):96-100. PubMed ID: 14727249
[TBL] [Abstract][Full Text] [Related]
12. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck.
Haddad R; Wirth L; Costello R; Weeks L; Posner M
Semin Oncol; 2003 Dec; 30(6 Suppl 18):84-8. PubMed ID: 14727246
[TBL] [Abstract][Full Text] [Related]
13. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
Braaksma M; Levendag P
Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
[TBL] [Abstract][Full Text] [Related]
14. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
Thorstad WL; Chao KS; Haughey B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
[TBL] [Abstract][Full Text] [Related]
15. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
